Revance Therapeutics (Revance Therapeutics) COGS-to-Revenue : 0.29 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Revance Therapeutics COGS-to-Revenue?

Revance Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2024 was $14.9 Mil. Its Revenue for the three months ended in Mar. 2024 was $51.9 Mil.

Revance Therapeutics's COGS to Revenue for the three months ended in Mar. 2024 was 0.29.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Revance Therapeutics's Gross Margin % for the three months ended in Mar. 2024 was 71.29%.

Revance Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Revance Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics COGS-to-Revenue Chart

Revance Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.31

0.30

0.39

0.32

Revance Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.27	0.37	0.34	0.25	0.29

Revance Therapeutics COGS-to-Revenue Calculation

Revance Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	74.363	/	234.04
	=	0.32

Revance Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	14.911	/	51.936
	=	0.29

Revance Therapeutics (NAS:RVNC) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Revance Therapeutics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	14.911 / 51.936
	=	71.29 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Revance Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Revance Therapeutics (Revance Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (NAS:RVNC) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

RTI:Germany

Address

1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203

Website

https://www.revance.com

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Executives

Dwight Moxie	officer: SVP, GC & Secretary	7555 GATEWAY BOULEVARD, NEWARK CA 94560
Mark J Foley	director	ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Tobin Schilke	officer: Chief Financial Officer	7000 SHORELINE COURT, #371, SOUTH SAN FRANCISCO CA 94080
Carey Oconnor Kolaja	director	C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, SUITE 1001, NASHVILLE TN 37203
Dustin S Sjuts	officer: President	7555 GATEWAY BLVD, NEWARK CA 94560
Vlad Coric	director	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Aubrey Rankin	director	C/O REVANCE THERAPEUTICS, INC, 7555 GATEWAY BLVD, NEWARK CA 94560
Angus C. Russell	director	C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Olivia C Ware	director	11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Chris Nolet	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Jill Beraud	director	C/O LEVI STRAUSS & CO., 1155 BATTERY STREET, SAN FRANCISCO CA 94111
L Daniel Browne	director, officer: CEO and President	7555 GATEWAY BOULEVARD, NEWARK CA 94560
Cyril Allouche	officer: Principal Financial Officer	7555 GATEWAY BLVD., NEWARK CA 94560
Lauren P Silvernail	officer: CFO, Seretary & EVP Corp Dev.	15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Caryn Gordon Mcdowell	officer: SVP, GC & Secretary	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080